Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients.
Rieke E AltenGerd R BurmesterMarco Matucci-CerinicJean-Hugues SalmonAndrew ÖstörKhai Jing NgJens GerwienLiliana Zaremba-PechmannAlan J M BrnabicBruno FautrelPublished in: Rheumatology and therapy (2023)
This real-world data can better inform clinicians about baricitinib effectiveness and drug survival when prescribing treatment for patients with RA across different subpopulations.
Keyphrases
- patient reported outcomes
- rheumatoid arthritis
- disease activity
- end stage renal disease
- electronic health record
- newly diagnosed
- primary care
- ejection fraction
- randomized controlled trial
- ankylosing spondylitis
- big data
- systematic review
- peritoneal dialysis
- palliative care
- adverse drug
- machine learning
- systemic sclerosis
- deep learning
- data analysis
- free survival